Beyond the Science: The Business of Drug Development

E-TEXTBOOK

Almost $3 billion is spent developing one prescription drug to gain market approval¹. Why? Who decides where the money is allocated and which trials to push forward with? Whether you're working at a lab bench or new to the industry, understanding the business beyond the science is crucial to a successful career in drug discovery and development.

That's why BioPharma Dive and Bridging BioScience & BioBusiness designed the 13-chapter e-textbook Beyond the Science: The Business of Drug Development to cover all the basic business activities, strategies, insights, and issues for biotech/pharma organizations, large and small.

From the role of clinical trials to pharmacoeconomics, drug pricing, and policy, the book will help you connect the dots between the science and business of the biopharma industry.

Purchase the e-textbook to learn:

• The lingo and role of CROs, CMOs, NDAs, and BLAs.
• Why small biotech drug discovery & development companies can spend ten-fold less than big pharma on discovery and development
• Why patent fences are necessary and the role of a company's intellectual property committee
• The importance of pharmacoeconomic considerations throughout the entire process—from drug discovery through sales
• How overpricing drugs can decimate sales—and how exactly to price drugs to optimize revenue
• The complex drug development and business behind drugs for rare diseases

¹Based upon the 2014 study by Joseph A. DiMasi, Tufts Center for the Study of Drug Development.